Related Experiment Video
Updated: Sep 28, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
[Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer]
Rong Wang1, Sisi Pan2, Xia Song1
1The Second Department of Respiratory, Shanxi Provincial Cancer Hospital, Taiyuan 030000, China.
Abstract:
With the rapid development and wide application of next generation sequencing (NGS) technology, a series of researches have revealed that concurrent genetic alterations play an important role in the response and resistance of epidermal growth factor receptor (EGFR)-mutant NSCLC to EGFR-tyrosine kinase inhibitor (TKI). Besides, TP53 mutation is the most common co-mutation gene in EGFR-mutant NSCLC, which has been proved to confer a worse prognosis in EGFR-mutated patients treated with first, second and third generation of EGFR-TKIs. Currently, it is still being explored how to select the best treatment strategies for patients with concomitant presence of TP53 mutation in EGFR-mutant NSCLC. Here, we review the literature on recent research progress of TP53 concurrent mutation in EGFR-mutant advanced NSCLC. .
Insights
Concurrent TP53 mutations in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) are linked to poorer outcomes with EGFR-tyrosine kinase inhibitors (TKIs). Research is ongoing to optimize treatments for these patients.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Next-generation sequencing (NGS) reveals concurrent genetic alterations impact EGFR-mutant NSCLC response to TKIs.
- TP53 mutations are common co-mutations in EGFR-mutant NSCLC, associated with worse prognosis across multiple TKI generations.
Purpose of the Study:
- To review recent research on TP53 concurrent mutations in EGFR-mutant advanced NSCLC.
- To explore optimal treatment strategies for patients with co-occurring TP53 and EGFR mutations.
Main Methods:
- Literature review of recent research progress.
- Analysis of studies investigating TP53 concurrent mutation in EGFR-mutant NSCLC.
Main Results:
- TP53 co-mutation is a significant factor influencing treatment outcomes in EGFR-mutant NSCLC.
- Current treatment selection for patients with TP53 co-mutation remains an area of active investigation.
Conclusions:
- Understanding the impact of TP53 mutations is crucial for personalized treatment of EGFR-mutant NSCLC.
- Further research is needed to develop effective therapeutic strategies for patients with concurrent TP53 mutations.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...